CD58 and acute lymphoblastic leukemia: Furthermore, CD58-mediated CRISPR/Cas9 knockout in ALL cells in vitro failed to trigger T cell activation and proliferation in the presence of the immunotherapeutic agent blinatumomab, thus decreasing its sensitivity (Li et al., 2022).